Alumis Inc. (NASDAQ:ALMS) Receives Average Rating of “Buy” from Brokerages

Shares of Alumis Inc. (NASDAQ:ALMS) have earned a consensus rating of “Buy” from the eight analysts that are currently covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $26.83.

ALMS has been the topic of a number of research analyst reports. HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of Alumis in a research note on Friday, December 20th. Baird R W upgraded shares of Alumis to a “strong-buy” rating in a research report on Thursday, October 31st. Robert W. Baird started coverage on shares of Alumis in a research report on Thursday, October 31st. They set an “outperform” rating and a $25.00 target price for the company. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Alumis in a report on Thursday, November 14th.

Institutional Investors Weigh In On Alumis

A number of hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets bought a new position in shares of Alumis during the 3rd quarter valued at $27,000. MetLife Investment Management LLC bought a new position in shares of Alumis during the third quarter valued at about $89,000. JPMorgan Chase & Co. purchased a new position in shares of Alumis in the third quarter worth about $191,000. Barclays PLC bought a new stake in shares of Alumis in the 3rd quarter valued at about $197,000. Finally, Maven Securities LTD purchased a new stake in Alumis during the 2nd quarter valued at about $332,000.

Alumis Trading Down 6.7 %

Alumis stock opened at $7.52 on Tuesday. Alumis has a fifty-two week low of $7.46 and a fifty-two week high of $13.53. The stock has a fifty day moving average price of $9.81.

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.